# Horizon 3

> Horizon 3 is a VC fund backing Biotechnology and Agriculture. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: 's-hertogenbosch, The Netherlands
- Total investments: 3
- Last investment: Mar 2025
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://www.horizon3.nl

Horizon 3 is an innovation platform for high-tech start-ups within the biobased economy.

## Contacts

5 contacts available for Horizon 3. Shizune tracks 1 team members at Horizon 3. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/horizon-3-04dc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Agriculture | 1 | 33% |
| Health Care | 1 | 33% |
| Manufacturing | 1 | 33% |
| Medical Device | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 33% |
| Series D | 1 | 33% |
| Series E | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 33% |
| The Netherlands | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bart Raedts | Director & founder | 0 | https://shizune.co/investors/profile/bart-raedts |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cardiac Dimensions | Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M | Series E | Mar 20, 2025 |  |
| Cardiac Dimensions | Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $35M | Series D | Jan 05, 2023 |  |
| ChainCraft | ChainCraft develops mixed culture fermentation technologies in order to produce sustainable biobased chemicals that are able to compete with current state of the industry-produced chemicals. | $10.9M | Series C | Sep 06, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Hostplus](https://shizune.co/investors/profile/hostplus) — VC Fund, 2 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together
- [M. H. Carnegie & Co.](https://shizune.co/investors/profile/m-h-carnegie-co) — VC Fund, 2 deals together
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 1 deal together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 1 deal together
- [Convent Capital](https://shizune.co/investors/profile/convent-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Horizon 3 invest in?

Horizon 3 invests primarily in Biotechnology, Agriculture and Health Care startups, most often at Series C and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Horizon 3?

Public channels for Horizon 3 include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Horizon 3?

The team at Horizon 3 includes Bart Raedts (Director & founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co